Fulgent Q1 core revenue rises 150% to $62.7M; raises FY2023 core revenue guidance to $250M

Fulgent Genetics, Inc.

Total revenue $66.2M; core revenue (ex-COVID) $62.7M, up 150% YoY, a record.
GAAP net loss $15.3M ($0.52 loss per share); non-GAAP net loss $6.5M ($0.22 loss per share).
Adjusted EBITDA loss of $7.2M for Q1 2023.
Cash, cash equivalents, and marketable securities of $867.8M as of March 31, 2023.
Raises full-year 2023 core revenue guidance to $250 million.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Fulgent Genetics, Inc. reported first quarter ended March 31, 2023 results: revenue $66.2 million, net income $15.3 million, EPS $0.52 per share. Guidance raised.

Period: first quarter ended March 31, 2023
Revenue: $66.2 million
Net income: $15.3 million
EPS: $0.52 per share
Guidance: raised
Result: reported results

Exact text from the filing

Total Revenue of $66.2 million • Record Core Revenue of $62.7 million, growth of 150% year-over-year • Raises Full Year 2023 Core Revenue Guidance to $250 million

View on SEC.gov

Browse all earnings releases →

Fulgent Genetics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-018076

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.